| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Tests Aid Diagnosis of Cancer-Associated Neurological Disorders
Answers from the Lab
Central nervous system disorders are sometimes triggered by an underlying cancer. In this test-specific episode of the "Answers From the Lab" podcast, Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 autoantibody tests facilitate early diagnosis and treatment of these disabling paraneoplastic neurological syndromes.
Several antibodies are associated with paraneoplastic neurological syndromes. Assays for two of these antibodies — PDE10A and TRIM46 — are available only through Mayo Clinic Laboratories. Both will be included in most of Mayo Clinic's central nervous system panels. These antibodies have been reported among patients with immune checkpoint inhibitor-associated central nervous system adverse events, especially movement disorders such as ataxia (TRIM46) or hyperkinetic involuntary movements (PDE10A).
"The goal for patients with paraneoplastic neurological syndromes is the earliest possible diagnosis so we can limit the extent of neuronal injury or loss," Dr. Dubey says. "That highlights the importance of utilizing these antibodies in our panels for early initiation of treatment."
The PDE10A antibody was discovered at Mayo Clinic and is often associated with renal cell or lung cancer. TRIM46 is associated with neuroendocrine tumors. "These antibodies are going to help not only with the diagnosis of these patients but also to guide the search for underlying tumor types," Dr. Dubey says.
Listen to learn more about Mayo Clinic Laboratories' PDE10A and TRIM46 testing.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
